Seminars in Radiation Oncology
Volume 18, Issue 4 , Pages 249-256 , October 2008

Rationale, Conduct, and Outcome Using Hypofractionated Radiotherapy in Prostate Cancer

  • Mark Ritter, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mark Ritter, MD, PhD, Department of Human Oncology and Medical Physics, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K4/B100, Madison, WI 53792

References 

  1. Bentzen SM, Overgaard J, Thames HD, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol. 1989;16:169–182
  2. Thames HD, Suit HD. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys. 1986;12:687–691
  3. Haustermans KM, Hofland I, Van Poppel H, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:1067–1070
  4. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994;74:670–678
  5. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  6. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? (Rationale for hypofractionated high-dose-rate brachytherapy). [editorial] Int J Radiat Oncol Biol Phys. 1999;44:747–748
  7. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  8. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  9. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  10. D'Souza WD, Thames HD. Is the a/b ratio for prostate cancer low?. Int J Radiat Biol Oncol Phys. 2001;51:1–3
  11. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;55:194–203
  12. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391–401
  13. Fowler JF, Nahum AE, Orton CG. Point/counterpoint (The best radiotherapy for the treatment of prostate cancer involves hypofractionation). Med Phys. 2006;33:3081–3084
  14. Douglas BG, Fowler JF. The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. Radiat Res. 1976;66:401–426
  15. Hall EJ, Brenner DJ. Extrapolating hypofractionated radiation schemes from radiosurgery data: Regarding Hall et al (IJROBP 21:819-824; 1991 and Hall and Brenner, IJROBP 25:381-385; 1993). Int J Radiat Oncol Biol Phys. 1995;32:275–276
  16. Brenner DJ, Hlatky LR, Hahnfeldt PJ, et al. A convenient extension of the linear-quadratic model to include redistribution and reoxygenation. Int J Radiat Oncol Biol Phys. 1995;32:379–390
  17. Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol. 2004;49:4825–4835
  18. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;56:1093–1104
  19. Kupelian PA, Reddy CA, Carlson TP, et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:904–912
  20. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  21. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991;3:127–132
  22. Duncan W, Warde P, Catton CN, et al. Carcinoma of the prostate: Results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys. 1993;26:203–210
  23. Read G, Pointon RC. Retrospective study of radiotherapy in early carcinoma of the prostate. Br J Urol. 1989;63:191–195
  24. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254–1259
  25. Akimoto T, Muramatsu H, Takahashi M, et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2004;60:1033–1039
  26. Tsuji H, Yanagi T, Ishikawa H, et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63:1153–1160
  27. Higgins GS, McLaren DB, Kerr GR, et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:982–989
  28. Soete G, Arcangeli S, De Meerleer G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. Radiother Oncol. 2006;80:78–81
  29. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;69:1084–1089
  30. Ritter MA, Forman JD, Kupelian PA, et al. A phase I/II trial of dose-per-fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69:S174
  31. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–6138
  32. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083
  33. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526
  34. Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: Ingredients for testing hypofractionation in prostate cancer—The CHHiP Trial. Clin Oncol (R Coll Radiol). 2008;20:12–14
  35. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really?. Radiother Oncol. 2005;76:1–3
  36. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105
  37. Pawlicki T, Cotrutz C, King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol. 2007;40:395–406
  38. Tang C, Loblaw DA, Cheung P, et al. Condensing external beam radiotherapy to five fractions for low-risk localized prostate cancer (Early results of pHART3). In: San Francisco, CA: ASCO 2008 Genitourinary Cancer Symposium; 2008;p. 148;February 14-16

PII: S1053-4296(08)00036-2

doi: 10.1016/j.semradonc.2008.04.007

Seminars in Radiation Oncology
Volume 18, Issue 4 , Pages 249-256 , October 2008

Article Tools

* Image Usage & Resolution